Welcome Guest!  Login | Register | Help
Home News Screener Maps Groups Portfolio Insider Futures Forex Collaborate Store Elite
Settings
GILD [NASD]
Gilead Sciences Inc.
IndexS&P 500 P/E25.17 EPS (ttm)4.45 Insider Own0.40% Shs Outstand1.51B Perf Week1.17%
Market Cap169.31B Forward P/E11.61 EPS next Y9.65 Insider Trans0.40% Shs Float1.49B Perf Month7.12%
Income7.46B PEG1.09 EPS next Q1.92 Inst Own92.70% Short Float3.22% Perf Quarter21.50%
Sales17.44B P/S9.71 EPS this Y10.40% Inst Trans-0.07% Short Ratio3.32 Perf Half Y40.30%
Book/sh10.50 P/B10.67 EPS next Y19.93% ROA28.60% Target Price118.08 Perf Year57.35%
Cash/sh5.82 P/C19.24 EPS next 5Y23.00% ROE57.70% 52W Range63.50 - 114.35 Perf YTD49.13%
Dividend- P/FCF24.64 EPS past 5Y11.90% ROI18.70% 52W High-2.06% Beta0.74
Dividend %- Quick Ratio2.20 Sales past 5Y16.00% Gross Margin81.20% 52W Low76.38% ATR3.99
Employees6100 Current Ratio2.50 Sales Q/Q136.10% Oper. Margin56.20% RSI (14)58.59 Volatility3.87% 4.03%
OptionableYes Debt/Eq0.59 EPS Q/Q378.30% Profit Margin42.80% Rel Volume1.53 Prev Close114.22
ShortableYes LT Debt/Eq0.49 EarningsOct 28 AMC Payout0.00% Avg Volume14.41M Price112.00
Recom1.70 SMA206.13% SMA505.75% SMA20027.75% Volume22,044,016 Change-1.94%
29-Oct-14Reiterated RBC Capital Mkts Outperform $115 → $125
13-Oct-14Reiterated FBR Capital Outperform $125 → $130
25-Sep-14Reiterated Needham Buy $95 → $120
22-Aug-14Reiterated RBC Capital Mkts Outperform $102 → $115
15-Aug-14Initiated FBR Capital Outperform $125
11-Aug-14Reiterated Argus Buy $90 → $110
28-Jul-14Reiterated Maxim Group Buy $112 → $127
24-Jul-14Reiterated RBC Capital Mkts Outperform $96 → $102
28-Apr-14Reiterated Maxim Group Buy $101 → $112
21-Feb-14Reiterated Barclays Overweight $90 → $95
10-Feb-14Reiterated Argus Buy $84 → $90
05-Feb-14Reiterated RBC Capital Mkts Outperform $90 → $96
05-Feb-14Reiterated Needham Buy $85 → $95
05-Feb-14Reiterated Maxim Group Buy $98 → $101
04-Feb-14Upgrade Robert W. Baird Neutral → Outperform $65 → $103
28-Jan-14Reiterated Deutsche Bank Buy $95 → $132
06-Jan-14Reiterated UBS Buy $80 → $102
02-Jan-14Reiterated Maxim Group Buy $89 → $98
20-Dec-13Reiterated RBC Capital Mkts Outperform $80 → $90
01-Nov-13Reiterated Argus Buy $70 → $84
31-Oct-14 05:36PM  Fundamentals, Technicals Still Intact At Gilead Sciences at Investor's Business Daily
05:26PM  Today's Market Thorns, Roses, All Time Highs, and ETF All Time Highs Yahoo Finance Blogs
02:25PM  AbbVie Beats Q3 Earnings Estimates, Raises Guidance at Investor's Business Daily
11:48AM  Gilead Sciences: Harvoni Still Selling Like Hotcakes at Barrons.com
06:00AM  Jim Cramer's Top Stock Picks: CELG REGN GILD BIIB TTWO CRL FLEX at TheStreet
30-Oct-14 08:11PM  Jim Cramer's 'Mad Money' Recap: Here's Why the Bears Were Dead Wrong at TheStreet
05:54PM  [video]Netflix and Gilead Will See More Gains, Says Thornburg Value Manager at TheStreet
05:31PM  Veeva Systems Flies High On Cloud For Life Sciences at Investor's Business Daily
05:21PM  Market Thorns, Roses, All Time Highs, and ETF All Time Highs... Yahoo Finance Blogs
05:21PM  Facebook, Twitter, Amazon And Gilead: Musketeers Wielding Blunted Swords? at Forbes
03:42PM  [video]Phibro, Gilead Will See More Gains Says Thornburg Value Manager at TheStreet
08:55AM  Top Health Care and Biotech Stocks to Buy That Have Already Posted Earnings at 24/7 Wall St.
29-Oct-14 02:56PM  [$$] Gilead: Buy the Dip at Barrons.com
12:37PM  4 Stocks, 4 trades: GT, PNRA, HSY & GILD CNBC
11:26AM  Limited downside seen in Gilead optionMONSTER
10:50AM  Gilead Sciences Suffers 'Sloppy' Quarter on 'Unimportant' Sovaldi Sales at Barrons.com
10:37AM  Gilead Sciences (GILD) Stock Declines After Weak Third-Quarter Results at TheStreet
10:31AM  Stocks Stage Mixed Start; Facebook Drags Down Nasdaq at Investor's Business Daily
09:30AM  Gilead Sciences (GILD) Earnings Report: Q3 2014 Conference Call Transcript at TheStreet
09:22AM  Cramer's Mad Dash: US Steel leaner & meaner CNBC
08:00AM  Gilead Beats on Q3 Earnings, Sovaldi Sales Fall Sequentially Zacks
07:55AM  Gilead Sciences Earnings Miss on Dwindling Sovaldi Sales 24/7 Wall St.
05:53AM  Warren Buffett best wear his trunks as Fed preps to end (pause) the printing at MarketWatch
12:34AM  [$$] Sales of Gileads Pricey Hepatitis Drug Slow at The Wall Street Journal
28-Oct-14 11:02PM  Gilead (GILD) Posts Weak Earnings; Stock Falls 4% After-Hours Zacks
08:17PM  Low Drug Sales Drag Down Shares of Sanofi and Gilead at New York Times
08:03PM  Top Holdings Of Top Health Care Funds: Alexion, Gilead, Celgene at Investor's Business Daily
06:53PM  Gilead Earnings, Sales Growth Surge, But Slow On Weaker Sovaldi Demand Investor's Business Daily
06:47PM  Gilead beats Street 3Q forecasts AP
06:27PM  Civitas Buyout Shores Up Acorda's Wall Street Cred at Investor's Business Daily
06:17PM  Gilead third-quarter Sovaldi sales dip, but net profit triples Reuters
05:39PM  [$$] Gilead's Hepatitis Drug Sees Sales Slow at The Wall Street Journal
05:38PM  Gilead Sciences' Earnings Miss Forecasts as ACA Drives Higher Costs at Barrons.com
05:16PM  Gilead sinks on earnings CNBC
04:49PM  Gilead stock falls on Sovaldi sales miss at CNBC
04:31PM  Updates, advisories and surprises at MarketWatch
04:30PM  Gilead Sciences Inc Earnings Call scheduled for 4:30 pm ET today CCBN
04:27PM  Gilead third-quarter profit triples as sales more than double Reuters
04:23PM  Earnings roundup: FB, EA, GILD, INVN & ESRX CNBC
04:22PM  Gilead Sciences (GILD) Stock Falls in After-Hours Trading After Earnings Miss at TheStreet
04:20PM  Gilead Reports Lower-Than-Estimated Sales of Sovaldi at Bloomberg
04:14PM  Gilead Sciences' stock pulls back from record high close after earnings miss at MarketWatch
04:08PM  GILEAD SCIENCES INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhib EDGAR Online
04:05PM  Gilead Sciences Announces Third Quarter 2014 Financial Results Business Wire
02:39PM  Bonds hold losses after weak 2-year note auction at CNBC
12:38PM  Aetna Falls On Costs; Centene Rises On Medicaid Gains at Investor's Business Daily
12:02PM  Earnings Preview: Facebook and Gilead Sciences on Deck Yahoo Finance Blogs
11:55AM  What to Look For in Gilead Sciences Earnings Report at 24/7 Wall St.
11:55AM  What to Expect When Gilead (GILD) Reports Third-Quarter Earnings Today at TheStreet
10:30AM  Gilead Sciences Earnings: What To Watch at The Wall Street Journal
09:46AM  Today Gilead (GILD) Hits New Lifetime High at TheStreet
08:00AM  #PreMarket Primer: Tuesday, October 28: CDC Warns That Involuntary Quarantines Could Discourage Progress On Ebola Benzinga
07:07AM  Q3 2014 Gilead Sciences Inc Earnings Release - 4:05 pm ET CCBN
03:04AM  Here's the wonder drug that will quadruple Gilead's 3rd quarter profits Yahoo Finance Blogs
27-Oct-14 08:56PM  Twitter Results and Outlook Send Stock Down 12% Yahoo Finance Blogs
05:04PM  Today's Market Thorns, Roses, and All Time Highs... Yahoo Finance Blogs
03:39PM  [$$] Biotech Bull Intact But Showing Signs of Age at Barrons.com
03:38PM  Gilead Rises Ahead Of Q3 Earnings As Rivals Wobble at Investor's Business Daily
03:12PM  If It's Bad For Merck, It's Good For Gilead at Barrons.com
02:49PM  [$$] Gilead Stock Should Move Big on Earnings Report at Barrons.com
01:43PM  What's boosting healthiest sector in S&P this year at CNBC
11:25AM  Bull case for biotech CNBC
11:25AM  Biotech's wild ride CNBC
08:19AM  #PreMarket Primer: Monday, October 27: ECB Stress Tests In-Line With Expectations Benzinga
24-Oct-14 04:56PM  Stocks Put End To Four-Week Slide at Investor's Business Daily
04:19PM  Stocks Cap Week With Solid Gains; Gilead Clears Buy Point at Investor's Business Daily
02:39PM  Will Gilead (GILD) Miss Earnings on High Operating Costs? Zacks
01:12PM  Biotech leading Nasdaq CNBC
09:55AM  Cramer's Stop Trading: Celgene CNBC
09:32AM  Gilead Sciences: Harvoni "Off to the Races" at Barrons.com
08:21AM  High Drug Prices Could Increase Industry Innovation at Forbes
23-Oct-14 03:08PM  Alexion Pharmaceuticals: Nice Earnings, Too Expensive? at Barrons.com
09:51AM  Could High Drug Prices Be Bad For Innovation? at Forbes
22-Oct-14 05:01PM  Biotechs Show Fed Chief's Not Much Of A Stock Analyst at Investor's Business Daily
04:44PM  Gilead's Hep C Dream Drug Faces Demanding Investors at Investor's Business Daily
12:14PM  Value in biotech: Pro CNBC
21-Oct-14 07:56PM  Biogen Leads 5 Top Biotech Stocks As Earnings Loom at Investor's Business Daily
05:00PM  Gilead Sciences to Release Third Quarter 2014 Financial Results on Tuesday, October 28, 2014 Business Wire
12:00PM  How Gilead Sciences Became A Big Name In Biotech at Investopedia
20-Oct-14 04:37PM  Will High Price Hurt Gilead Sciences' New Hep-C Drug? at Barrons.com
11:56AM  Senate Lawmaker Eyes Hearing on the Cost of Hepatitis C Treatments at The Wall Street Journal
08:05AM  #PreMarket Primer: Monday, October 20: Fed To Tread Softly At October Meeting Benzinga
17-Oct-14 07:17PM  Lightning Round: Seadrill, Gilead & More at CNBC
05:03PM  Perrigo CEO Constructs "Five Pillars" For Success at Investor's Business Daily
04:24PM  Stocks Up Big Friday, Recover Early Week Losses at Investor's Business Daily
03:30PM  Gilead's Harvoni Receives Notice of Compliance from Canada Zacks
03:29PM  The top 10 best-performing CEOs at Fortune
16-Oct-14 02:44PM  Health Canada issues notice of compliance for Gilead's Harvoni (ledipasvir/sofosbuvir), the first once-daily single tablet regimen for the treatment of genotype 1 chronic hepatitis C PR Newswire
02:44PM  Health Canada issues notice of compliance for Gilead's Harvoni (ledipasvir/sofosbuvir), the first once-daily single tablet regimen for the treatment of genotype 1 chronic hepatitis C CNW Group
01:30PM  Health Canada Issues Notice of Compliance for Gileads Harvoni (Ledipasvir/Sofosbuvir), the First Once-Daily Single Tablet Regimen for the Treatment of Genotype 1 Chronic Hepatitis C Business Wire
12:18PM  Buy These Five Beaten-Down Biotech Stocks, Nomura Says at Barrons.com
15-Oct-14 04:20PM  Novavax Begins Mid-Stage Study on RSV Vaccine in Elders Zacks
12:59PM  Biotech Stock Roundup: Gilead Nabs FDA Nod for Combo HCV Drug, Auxilium Accepts Endo Offer Zacks
09:35AM  Stock Weakness in Seattle Genetics, Gilead Sciences Belies Fundamental Strengths at TheStreet
09:02AM  Is Specialty Pharma Pricing At A Tipping Point? at Forbes
14-Oct-14 06:49PM  Gilead Investor's Business Daily
05:47PM  Market Thorns, Roses, and All Time Highs... Yahoo Finance Blogs
05:09PM  Wall Street Ends Mixed; Airlines Soar As Oil Plunges at Investor's Business Daily
04:41PM  US STOCKS- S&P 500, Nasdaq break 3-day slide but Dow dips Reuters
04:23PM  Stocks Close Mixed, Surrendering Some Early Gains at Investor's Business Daily
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines for the treatment of life threatening diseases in North America, South America, Europe, and the Asia-Pacific. The company's products include Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost, and Vitekta for the treatment of human immunodeficiency virus (HIV) infection in adults; and Sovaldi, Viread, and Hepsera products for the treatment of liver disease. It also offers Letairis, an endothelin receptor antagonist for the treatment of pulmonary arterial hypertension; Ranexa, a tablet used for the treatment of chronic angina; Lexiscan/Rapiscan injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging; Cayston, an inhaled antibiotic for the treatment of respiratory systems in cystic fibrosis patients; and Tamiflu, an oral antiviral capsule for the treatment and prevention of influenza A and B. In addition, the company provides other products, such as AmBisome, an antifungal agent to treat serious invasive fungal infections; Vistide, an antiviral injection for the treatment of cytomegalovirus retinitis in adult patients with AIDS; and Macugen, an anti-angiogenic oligonucleotide to treat neovascular age-related macular degeneration. Further, it has product candidates in various stages for the treatment of HIV, liver, oncology/inflammation, cardiovascular, and respiratory diseases. The company markets its products through its commercial teams and/or in conjunction with third-party distributors and corporate partners. Gilead Sciences, Inc. has collaborations with BMS, Janssen, and Japan Tobacco to develop and commercialize various products. The company was founded in 1987 and is headquartered in Foster City, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Carter Paul RutherfordEVP Commercial OpsOct 24Option Exercise40.562,00081,12034,244Oct 28 01:35 PM
Carter Paul RutherfordEVP Commercial OpsOct 24Sale110.002,000220,00732,244Oct 28 01:35 PM
Cogan John FrancisDirectorOct 21Option Exercise14.3415,000215,06357,405Oct 23 01:54 PM
Cogan John FrancisDirectorOct 21Sale104.0815,0001,561,14942,405Oct 23 01:54 PM
MILLIGAN JOHN FPresident and COOOct 07Option Exercise8.01146,8951,175,8941,120,943Oct 09 02:10 PM
MILLIGAN JOHN FPresident and COOOct 07Sale104.60146,89515,365,818974,048Oct 09 02:10 PM
Alton Gregg HEVP, Corp & Med AffairsOct 01Option Exercise23.7631,000736,405153,694Oct 03 02:53 PM
MARTIN JOHN CChairman and CEOOct 01Option Exercise8.01140,6251,125,7034,570,012Oct 03 02:57 PM
Alton Gregg HEVP, Corp & Med AffairsOct 01Sale105.9833,0003,497,259120,694Oct 03 02:53 PM
MARTIN JOHN CChairman and CEOOct 01Sale105.91140,62514,893,8454,429,387Oct 03 02:57 PM
Carter Paul RutherfordEVP Commercial OpsSep 26Option Exercise40.562,00081,12034,244Sep 30 01:19 PM
Carter Paul RutherfordEVP Commercial OpsSep 26Sale107.472,000214,94532,244Sep 30 01:19 PM
Cogan John FrancisDirectorSep 22Option Exercise14.345,00071,68847,405Sep 24 01:20 PM
Cogan John FrancisDirectorSep 22Sale106.605,000532,98742,405Sep 24 01:20 PM
MILLIGAN JOHN FPresident and COOSep 08Option Exercise8.01146,8951,175,8941,120,943Sep 10 04:06 PM
MILLIGAN JOHN FPresident and COOSep 08Sale105.99146,89515,569,664974,048Sep 10 04:06 PM
Alton Gregg HEVP, Corp & Med AffairsSep 02Option Exercise23.7631,000736,405155,694Sep 04 05:09 PM
MARTIN JOHN CChairman and CEOSep 02Option Exercise8.01140,6251,125,7034,570,012Sep 04 05:09 PM
Whitley Richard JamesDirectorSep 02Option Exercise26.995,000134,95020,641Sep 04 04:31 PM
Alton Gregg HEVP, Corp & Med AffairsSep 02Sale108.5833,0003,583,230122,694Sep 04 05:09 PM
MARTIN JOHN CChairman and CEOSep 02Sale108.64140,62515,277,9144,429,387Sep 04 05:09 PM
Whitley Richard JamesDirectorSep 02Sale108.105,000540,50015,641Sep 04 04:31 PM
Carter Paul RutherfordEVP Commercial OpsAug 26Option Exercise19.0910,000190,85042,244Aug 28 02:35 PM
Carter Paul RutherfordEVP Commercial OpsAug 26Sale106.1610,0001,061,61832,244Aug 28 02:35 PM
Cogan John FrancisDirectorAug 21Option Exercise14.345,00071,68847,405Aug 25 12:21 PM
Cogan John FrancisDirectorAug 21Sale101.095,000505,44042,405Aug 25 12:21 PM
Washington Robin LEVP, CFOAug 14Option Exercise40.5633,5561,361,03183,388Aug 18 01:10 PM
Washington Robin LEVP, CFOAug 14Sale95.5633,5563,206,61149,832Aug 18 01:10 PM
Carter Paul RutherfordEVP Commercial OpsAug 08Option Exercise26.9916,728451,48948,713Aug 12 04:25 PM
Carter Paul RutherfordEVP Commercial OpsAug 08Sale91.5816,7281,531,88131,985Aug 12 04:25 PM
MARTIN JOHN CChairman and CEOAug 01Option Exercise8.01140,6251,125,7034,570,012Aug 04 06:16 PM
Whitley Richard JamesDirectorAug 01Option Exercise26.995,000134,95020,641Aug 05 05:31 PM
Carter Paul RutherfordEVP Commercial OpsAug 01Option Exercise0.002,500033,205Aug 05 05:31 PM
Washington Robin LEVP, CFOAug 01Option Exercise22.3030,600682,49080,432Aug 05 01:35 PM
MARTIN JOHN CChairman and CEOAug 01Sale91.53140,62512,871,8134,429,387Aug 04 06:16 PM
Whitley Richard JamesDirectorAug 01Sale91.005,000455,00015,641Aug 05 05:31 PM
Washington Robin LEVP, CFOAug 01Sale91.4830,6002,799,34849,832Aug 05 01:35 PM
MOORE NICHOLAS GDirectorJul 28Option Exercise26.6245,0001,197,67545,000Jul 30 12:17 PM
MOORE NICHOLAS GDirectorJul 28Sale90.5645,0004,075,4030Jul 30 12:17 PM
Cogan John FrancisDirectorJul 21Option Exercise14.345,00071,68847,405Jul 23 01:31 PM
Cogan John FrancisDirectorJul 21Sale89.675,000448,34342,405Jul 23 01:31 PM
Carter Paul RutherfordEVP Commercial OpsJul 08Option Exercise26.9916,728451,48947,433Jul 10 01:41 PM
Carter Paul RutherfordEVP Commercial OpsJul 08Sale86.4516,7281,446,07430,705Jul 10 01:41 PM
MARTIN JOHN CChairman and CEOJul 01Option Exercise8.01140,6251,125,7034,570,012Jul 03 02:28 PM
Alton Gregg HEVP, Corp & Med AffairsJul 01Option Exercise23.6131,000731,853159,694Jul 03 03:14 PM
Whitley Richard JamesDirectorJul 01Option Exercise26.995,000134,95020,641Jul 02 04:24 PM
MARTIN JOHN CChairman and CEOJul 01Sale84.84140,62511,929,9614,429,387Jul 03 02:28 PM
Alton Gregg HEVP, Corp & Med AffairsJul 01Sale84.1233,0002,776,076126,694Jul 03 03:14 PM
Whitley Richard JamesDirectorJul 01Sale83.655,000418,25015,641Jul 02 04:24 PM
Washington Robin LEVP, CFOJun 30Sale83.9810,400873,40346,774Jul 02 01:44 PM
Cogan John FrancisDirectorJun 23Option Exercise14.345,00071,68847,405Jun 25 01:51 PM
Cogan John FrancisDirectorJun 23Sale81.825,000409,12342,405Jun 25 01:51 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOJun 16Option Exercise16.4090,0001,475,550209,302Jun 18 04:33 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOJun 16Sale80.9090,0007,280,784119,302Jun 18 04:33 PM
Carter Paul RutherfordEVP Commercial OpsJun 09Option Exercise26.9916,728451,48947,433Jun 11 12:59 PM
Carter Paul RutherfordEVP Commercial OpsJun 09Sale79.4316,7281,328,64530,705Jun 11 12:59 PM
Washington Robin LEVP, CFOJun 04Sale82.526,426530,27457,174Jun 05 05:46 PM
Whitley Richard JamesDirectorJun 02Option Exercise26.995,000134,95020,641Jun 04 05:18 PM
Alton Gregg HEVP, Corp & Med AffairsJun 02Option Exercise23.6031,000731,600161,694Jun 04 05:21 PM
MARTIN JOHN CChairman and CEOJun 02Option Exercise8.01140,6251,125,7034,570,012Jun 04 02:48 PM
MARTIN JOHN CChairman and CEOJun 02Sale81.32140,62511,435,8364,429,387Jun 04 02:48 PM
Alton Gregg HEVP, Corp & Med AffairsJun 02Sale81.3533,0002,684,514128,694Jun 04 05:21 PM
Whitley Richard JamesDirectorJun 02Sale80.955,000404,75015,641Jun 04 05:18 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOMay 14Option Exercise16.4090,0001,475,550209,302May 16 02:52 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOMay 14Sale80.6590,0007,258,752119,302May 16 02:52 PM
Carter Paul RutherfordEVP Commercial OpsMay 10Option Exercise0.005,000021,290May 13 02:27 PM
Alton Gregg HEVP, Corp & Med AffairsMay 08Option Exercise23.3340,000933,132170,694May 12 03:38 PM
MILLIGAN JOHN FPresident and COOMay 08Option Exercise8.01100,000800,5001,038,048May 09 06:58 PM
Alton Gregg HEVP, Corp & Med AffairsMay 08Sale80.0040,0003,200,000130,694May 12 03:38 PM
Washington Robin LEVP, CFOMay 06Option Exercise24.913,00074,71552,832May 08 07:13 PM
Washington Robin LEVP, CFOMay 06Sale79.913,000239,73049,832May 08 07:13 PM
Alton Gregg HEVP, Corp & Med AffairsMay 01Option Exercise21.5811,000237,325143,694May 05 05:23 PM
Whitley Richard JamesDirectorMay 01Option Exercise26.995,000134,95017,778May 05 05:36 PM
MARTIN JOHN CChairman and CEOMay 01Option Exercise8.01140,6251,125,7034,570,012May 05 05:52 PM
MARTIN JOHN CChairman and CEOMay 01Sale79.02140,62511,112,0344,429,387May 05 05:52 PM
Whitley Richard JamesDirectorMay 01Sale78.635,000393,15012,778May 05 05:36 PM
Alton Gregg HEVP, Corp & Med AffairsMay 01Sale79.0813,0001,028,024130,694May 05 05:23 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOApr 14Option Exercise16.4090,0001,475,550209,302Apr 16 12:34 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOApr 14Sale67.0390,0006,032,482119,302Apr 16 12:34 PM
Cogan John FrancisDirectorApr 08Option Exercise14.345,00071,68844,542Apr 10 02:52 PM
Carter Paul RutherfordEVP Commercial OpsApr 08Option Exercise24.4316,728408,68945,290Apr 10 03:52 PM
Carter Paul RutherfordEVP Commercial OpsApr 08Sale70.5316,7281,179,78228,562Apr 10 03:52 PM
Cogan John FrancisDirectorApr 08Sale70.555,000352,75539,542Apr 10 02:52 PM
MARTIN JOHN CChairman and CEOApr 01Option Exercise8.01140,6251,125,7034,570,012Apr 03 03:20 PM
Alton Gregg HEVP, Corp & Med AffairsApr 01Option Exercise21.5811,000237,325145,694Apr 03 03:20 PM
Whitley Richard JamesDirectorApr 01Option Exercise26.995,000134,95018,116Apr 03 04:00 PM
Whitley Richard JamesDirectorApr 01Sale73.095,000365,45013,116Apr 03 04:00 PM
Alton Gregg HEVP, Corp & Med AffairsApr 01Sale73.2013,000951,640132,694Apr 03 03:20 PM
MARTIN JOHN CChairman and CEOApr 01Sale73.26140,62510,302,0284,429,387Apr 03 03:20 PM
Cogan John FrancisDirectorMar 14Option Exercise14.3414,000200,72553,542Mar 18 12:56 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOMar 14Option Exercise16.4090,0001,475,550209,302Mar 18 01:36 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOMar 14Sale75.8990,0006,829,705119,302Mar 18 01:36 PM
Cogan John FrancisDirectorMar 14Sale76.4414,0001,070,10139,542Mar 18 12:56 PM
Carter Paul RutherfordEVP Commercial OpsMar 10Option Exercise21.5816,728360,90745,290Mar 12 01:39 PM
Carter Paul RutherfordEVP Commercial OpsMar 10Sale79.3216,7281,326,83328,562Mar 12 01:39 PM
Alton Gregg HEVP, Corp & Med AffairsMar 03Option Exercise21.5831,000668,825117,484Mar 05 02:50 PM
MARTIN JOHN CChairman and CEOMar 03Option Exercise8.01140,6251,125,7034,397,860Mar 05 02:51 PM
MARTIN JOHN CChairman and CEOMar 03Sale81.74140,62511,495,3264,257,235Mar 05 02:51 PM
Alton Gregg HEVP, Corp & Med AffairsMar 03Sale81.8433,0002,700,68784,484Mar 05 02:50 PM
Washington Robin LEVP, CFOFeb 28Option Exercise22.3030,600682,49080,432Mar 04 09:09 PM